ArticleMolecular biology reports2026
YTHDF proteins differentially regulate a subset of m6A-modified transcripts to restrain endothelial inflammation during homeostasis.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundN6-methyladenosine (m6A) modification of mRNAs through METTL3 maintains homeostasis in many cell types. The mechanism by which METTL3 complexes together with reader proteins, especially the YTH domain-containing protein, governs endothelial homeostasis is not yet fully understood. METHODS AND
resultsPrimary endothelial cells (HUVECs), EA.hy926 cells, and rat aortas were used to modulate METTL3 activity and assess gene expression changes by molecular and biochemical assays. m6A RNA immunoprecipitation and RNA-protein interaction analyses were performed to determine transcript-specific m6A modification and YTHDF-mediated regulation. Interplaying with METTL3 caused abrupt yet selective loss of eNOS gene expression while increasing inflammatory adhesion molecule gene expression in cultured endothelial cells (EC) and rat aorta. Interestingly, many other genes associated with endothelial function/inflammation/senescence including CD31, CD144, KLF2, p65, and p53 remained unaltered upon METTL3 inhbition. MeRIP analysis revealed significant m6A modifications of several gene transcript including eNOS, and inflammatory adhesion molecules. m6A modification of gene transcripts selectively stabilized eNOS while causing degradation of inflammatory adhesion molecules without affecting the stability of other genes such as p65. Interestingly, RIP analysis showed that YTHDF1 was preferentially bound to m6A-modified eNOS while YTHDF2 was selectively associated with inflammatory adhesion molecules, causing differential regulation. Moreover, we failed to detect association of YTHDF1 or YTHDF2 to m6A modified p65 and KLF2 transcript.
conclusionTaken together, the current study describes the essential role of the METTL3 complex in maintaining endothelial homeostasis through differential association of m6A modified gene transcripts with the reader proteins.
Indexed as
Identifiers
41848956What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.